Movement Alert｜Guardant Health Rises 5.05% in Regular Trading, Multiple Catalysts Drive Continued Rally

Market Focus06-25 22:31

On June 25, Guardant Health rose 5.05% in regular trading, trading at 143.47 USD/share, with turnover of $79.42 million. The stock continued its upward momentum driven by a convergence of positive catalysts accumulated over recent weeks.

On the news front, RBC Capital Markets initiated coverage on June 12 with an Outperform rating and a $185 price target, noting that only approximately 25% of metastatic cancer patients in the US currently receive genomic profiling, positioning Guardant as the market leader best poised to benefit from expanding adoption. Additionally, on June 11, the FDA approved Guardant360 CDx as a companion diagnostic for non-small cell lung cancer therapy. These developments build on Q1 results that significantly beat expectations, with adjusted EPS of -$0.45 versus the -$0.76 consensus estimate and revenue of $301.7 million versus the $279.2 million estimate. The company also raised its full-year revenue guidance to $1.30B-$1.32B, above the prior FactSet estimate of $1.27B.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1159506789?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 22:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1159506789","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Guardant Health Rises 5.05% in Regular Trading, Multiple Catalysts Drive Continued Rally","media":"Market Focus","content":"<p><p>On June 25, Guardant Health rose 5.05% in regular trading, trading at 143.47 USD/share, with turnover of $79.42 million. The stock continued its upward momentum driven by a convergence of positive catalysts accumulated over recent weeks.</p><p>On the news front, RBC Capital Markets initiated coverage on June 12 with an Outperform rating and a $185 price target, noting that only approximately 25% of metastatic cancer patients in the US currently receive genomic profiling, positioning Guardant as the market leader best poised to benefit from expanding adoption. Additionally, on June 11, the FDA approved Guardant360 CDx as a companion diagnostic for non-small cell lung cancer therapy. These developments build on Q1 results that significantly beat expectations, with adjusted EPS of -$0.45 versus the -$0.76 consensus estimate and revenue of $301.7 million versus the $279.2 million estimate. The company also raised its full-year revenue guidance to $1.30B-$1.32B, above the prior FactSet estimate of $1.27B.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Guardant Health Rises 5.05% in Regular Trading, Multiple Catalysts Drive Continued Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Guardant Health Rises 5.05% in Regular Trading, Multiple Catalysts Drive Continued Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-25 22:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 25, Guardant Health rose 5.05% in regular trading, trading at 143.47 USD/share, with turnover of $79.42 million. The stock continued its upward momentum driven by a convergence of positive catalysts accumulated over recent weeks.</p><p>On the news front, RBC Capital Markets initiated coverage on June 12 with an Outperform rating and a $185 price target, noting that only approximately 25% of metastatic cancer patients in the US currently receive genomic profiling, positioning Guardant as the market leader best poised to benefit from expanding adoption. Additionally, on June 11, the FDA approved Guardant360 CDx as a companion diagnostic for non-small cell lung cancer therapy. These developments build on Q1 results that significantly beat expectations, with adjusted EPS of -$0.45 versus the -$0.76 consensus estimate and revenue of $301.7 million versus the $279.2 million estimate. The company also raised its full-year revenue guidance to $1.30B-$1.32B, above the prior FactSet estimate of $1.27B.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GH","symbol_name":"Guardant Health Inc.","start_time":0,"source_url":"","article_id":"1159506789","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1159506789","pubTimestamp":1782397901,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 25, Guardant Health rose 5.05% in regular trading, trading at 143.47 USD/share, with turnover of $79.42 million. The stock continued its upward momentum driven by a convergence of positive...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GH":"Guardant Health Inc."},"translate_title":"动向提示|Guardant Health常规交易涨5.05%多重催化剂推动持续涨势","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1},"content_text":"On June 25, Guardant Health rose 5.05% in regular trading, trading at 143.47 USD/share, with turnover of $79.42 million. The stock continued its upward momentum driven by a convergence of positive catalysts accumulated over recent weeks.On the news front, RBC Capital Markets initiated coverage on June 12 with an Outperform rating and a $185 price target, noting that only approximately 25% of metastatic cancer patients in the US currently receive genomic profiling, positioning Guardant as the market leader best poised to benefit from expanding adoption. Additionally, on June 11, the FDA approved Guardant360 CDx as a companion diagnostic for non-small cell lung cancer therapy. These developments build on Q1 results that significantly beat expectations, with adjusted EPS of -$0.45 versus the -$0.76 consensus estimate and revenue of $301.7 million versus the $279.2 million estimate. The company also raised its full-year revenue guidance to $1.30B-$1.32B, above the prior FactSet estimate of $1.27B.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1159506789","isCrawlerRequest":true}